Suzanne M. Vautrinot
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
TD Cowen Lowers Parsons Price Target to $62. TD Cowen maintained its positive stance on Parsons but lowered its price target to $62. This adjustment places the firm's estimate slightly above the current average analyst target of $59.64. The company is also scheduled to report its third-quarter 2026 financial results on October 28, 2026.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CSX COO Retirement and Q3 Earnings Outlook Drive Investor Focus. CSX is managing a leadership transition after COO Michael Cory retired, with operational oversight shifting to the CEO. This change occurs as the railroad prepares to report third-quarter earnings, focusing investor attention on key metrics and cash flow valuation. The stock's position near its 52-week high has prompted discussions about whether the current price reflects fair value.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Wells Fargo, Merrill Lynch Pay $4.4M Fine for Commission Issues. Wells Fargo and Merrill Lynch agreed to pay $4.4 million to settle state regulator allegations regarding overcharged commissions on small-dollar trades. This regulatory action follows recent Q3 results that analysts suggest reset the company's narrative, with the stock currently trading near its 52-week low. The settlement is a modest financial event compared to the bank's overall scale and recent earnings performance.
Transaction History
| ECL | ▲ Buy | Grant | 130 | $0 | 6/30/2026 | View on chart |
| ECL | ▼ Sell | Open Market | 1,004 | $266K | 5/27/2026 | View on chart |
| ECL | ▲ Buy | Option Exercise | 2,000 | $251K | 5/22/2026 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 996 | $251K | 5/22/2026 | View on chart |
| PSN | ▲ Buy | Grant | 2,947 | $0 | 4/14/2026 | View on chart |
| ECL | ▲ Buy | Grant | 138 | $0 | 3/31/2026 | View on chart |
| CSX | ▲ Buy | Grant | 4,455 | $0 | 2/26/2026 | View on chart |
| ECL | ▲ Buy | Grant | 128 | $0 | 12/31/2025 | View on chart |
| ECL | ▲ Buy | Grant | 123 | $0 | 9/30/2025 | View on chart |
| ECL | ▼ Sell | Open Market | 1,354 | $383K | 8/19/2025 | View on chart |
| ECL | ▲ Buy | Option Exercise | 2,300 | $265K | 8/14/2025 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 946 | $265K | 8/14/2025 | View on chart |
| ECL | ▲ Buy | Grant | 126 | $0 | 6/30/2025 | View on chart |
| PSN | ▲ Buy | Grant | 2,682 | $0 | 4/15/2025 | View on chart |
| ECL | ▲ Buy | Grant | 134 | $0 | 3/31/2025 | View on chart |
| CSX | ▲ Buy | Grant | 5,694 | $0 | 2/14/2025 | View on chart |
| ECL | ▲ Buy | Grant | 144 | $0 | 12/31/2024 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 989 | $248K | 12/6/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 2,200 | $248K | 12/6/2024 | View on chart |
| ECL | ▲ Buy | Grant | 133 | $0 | 9/30/2024 | View on chart |
| ECL | ▲ Buy | Grant | 141 | $0 | 6/30/2024 | View on chart |
| PSN | ▲ Buy | Grant | 2,179 | $0 | 4/16/2024 | View on chart |
| ECL | ▲ Buy | Grant | 146 | $0 | 3/31/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 2,400 | $252K | 3/15/2024 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 1,118 | $251K | 3/15/2024 | View on chart |
| ECL | ▲ Buy | Option Exercise | 500 | $52K | 3/15/2024 | View on chart |
| ECL | ▼ Sell | Tax Withholding | 233 | $52K | 3/15/2024 | View on chart |
| CSX | ▲ Buy | Grant | 4,902 | $0 | 2/16/2024 | View on chart |
| ECL | ▲ Buy | Grant | 157 | $0 | 12/31/2023 | View on chart |
| ECL | ▲ Buy | Grant | 184 | $0 | 9/30/2023 | View on chart |
| ECL | ▲ Buy | Grant | 168 | $0 | 6/30/2023 | View on chart |
| PSN | ▲ Buy | Grant | 3,855 | $0 | 4/18/2023 | View on chart |
| ECL | ▲ Buy | Grant | 190 | $0 | 3/31/2023 | View on chart |
| CSX | ▲ Buy | Grant | 5,688 | $180K | 2/14/2023 | View on chart |
| ECL | ▲ Buy | Grant | 215 | $0 | 12/31/2022 | View on chart |
| ECL | ▲ Buy | Grant | 214 | $0 | 9/30/2022 | View on chart |
| ECL | ▲ Buy | Grant | 205 | $0 | 6/30/2022 | View on chart |
| WFC | ▲ Buy | Grant | 5,384 | $0 | 4/26/2022 | View on chart |
| PSN | ▲ Buy | Grant | 4,818 | $0 | 4/14/2022 | View on chart |
| ECL | ▲ Buy | Grant | 175 | $0 | 3/31/2022 | View on chart |
| CSX | ▲ Buy | Grant | 4,803 | $169K | 2/16/2022 | View on chart |
| ECL | ▲ Buy | Grant | 123 | $0 | 12/31/2021 | View on chart |
| ECL | ▲ Buy | Grant | 136 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RBC and Citi highlight Ecolab's pricing power and specialty chemical strength
Recent analyst notes from RBC Capital Markets and Citi have focused on Ecolab's ability to maintain pricing and organic growth. These firms view the company as a defensive option that may benefit from a weaker dollar. The positive sentiment aligns with the stock trading near its 52-week high, reflecting strong investor interest in its stable earnings profile.
RBC and Citi highlight Ecolab's pricing power and specialty chemical strength. Recent analyst notes from RBC Capital Markets and Citi have focused on Ecolab's ability to maintain pricing and organic growth. These firms view the company as a defensive option that may benefit from a weaker dollar. The positive sentiment aligns with the stock trading near its 52-week high, reflecting strong investor interest in its stable earnings profile.